Paysign, Inc. (PAYS) stock
Close on Nov 17, 2026Market cap $553.89MP/E 37.7Yield –
Earnings
Paysign's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Quarterly results
Revenue and earnings per share from each of Paysign's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Adj. EPS | Source |
|---|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Mar 23, 2027Expected | – | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Nov 9, 2026after the close | $30.80M | +42.6% | $0.11 | – | Release |
| Q2 FY2026ended Jun 30, 2026 | Aug 5, 2026after the close | $28.25M | +48.1% | $0.11 | $0.16 | Release |
| Q1 FY2026ended Mar 31, 2026 | May 12, 2026after the close | $28.04M | +50.8% | $0.09 | $0.17 | Release |
| Q4 FY2025ended Dec 31, 2025 | Mar 24, 2026after the close | $22.76M | +45.8% | $0.02 | $0.09 | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 12, 2025after the close | $21.60M | +41.5% | $0.04 | – | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 5, 2025after the close | $19.08M | +33.1% | $0.02 | $0.08 | Release |
| Q1 FY2025ended Mar 31, 2025 | May 8, 2025after the close | $18.60M | +40.9% | $0.05 | $0.09 | Release |
| Q4 FY2024ended Dec 31, 2024 | Mar 25, 2025after the close | $15.61M | +13.9% | $0.02 | $0.05 | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 5, 2024after the close | $15.26M | +23.1% | $0.03 | $0.05 | Release |
| Q2 FY2024ended Jun 30, 2024 | Jul 31, 2024after the close | $14.33M | +30.3% | $0.01 | $0.04 | Release |
| Q1 FY2024ended Mar 31, 2024 | May 7, 2024after the close | $13.20M | +30.7% | $0.01 | $0.03 | Release |
| Q4 FY2023ended Dec 31, 2023 | Mar 26, 2024after the close | $13.70M | +29.2% | $0.10 | $0.05 | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 7, 2023after the close | $12.40M | +17.0% | $0.02 | $0.04 | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 8, 2023after the close | $11.00M | – | $0.00 | $0.02 | Release |
| Q1 FY2023ended Mar 31, 2023 | May 10, 2023after the close | $10.10M | +23.2% | $0.00 | $0.01 | Release |
| Q4 FY2022ended Dec 31, 2022 | Mar 22, 2023after the close | $10.60M | +20.5% | $0.01 | $0.03 | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 8, 2022after the close | $10.60M | +35.9% | $0.02 | $0.04 | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 9, 2022after the close | – | – | – | – | Release |
| Q1 FY2022ended Mar 31, 2022 | May 11, 2022after the close | $8.20M | – | -$0.01 | $0.02 | Release |
| Q4 FY2021ended Dec 31, 2021 | Mar 22, 2022after the close | $8.80M | – | $0.00 | $0.02 | Release |
| Q3 FY2021ended Sep 30, 2021 | Nov 9, 2021after the close | $7.80M | – | -$0.01 | $0.02 | Release |
| Q2 FY2021ended Jun 30, 2021 | Aug 10, 2021after the close | – | – | – | – | Filing |
| Q1 FY2021ended Mar 31, 2021 | May 12, 2021after the close | – | – | – | – | Filing |
| Q4 FY2020ended Dec 31, 2020 | Mar 25, 2021after the close | – | – | – | – | Filing |
| Q3 FY2020ended Sep 30, 2020 | Nov 17, 2020after the close | – | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Current guidance
Paysign's latest outlook for periods it has not reported yet, compared with what it said before
| Metric | Period | Guidance | Before | Change | Given |
|---|---|---|---|---|---|
| RevenueGAAP | FY2026 | $114.00M – $117.00M | – | New | Nov 9, 2026 |
| Revenue | FY2026 | $114.00M – $117.00M | $106.50M – $110.50M | Raised | Aug 5, 2026 |
| year-over-year growth | FY2026 | +30% – +35% | – | New | Mar 24, 2026 |
| Gross margin | FY2026 | 62% – 63% | 60% – 62% | Raised | Aug 5, 2026 |
| Gross profit marginGAAP | FY2026 | 63.5% – 64.5% | – | New | Nov 9, 2026 |
| Adjusted EBITDAnon-GAAP | FY2026 | $38.50M – $40.00M | – | New | Nov 9, 2026 |
| Adjusted EBITDAnon-GAAP | FY2026 | $35.00M – $38.00M | $30.00M – $33.00M | Raised | Aug 5, 2026 |
| Diluted EPSGAAP | FY2026 | $0.37 – $0.38 | – | New | Nov 9, 2026 |
| Diluted EPSGAAP | FY2026 | $0.35 – $0.37 | $0.21 – $0.26 | Raised | Aug 5, 2026 |
| Adj. EBITDA per diluted sharenon-GAAP | FY2026 | $0.57 – $0.61 | $0.49 – $0.53 | Raised | Aug 5, 2026 |
| depreciation and amortization expense | FY2026 | $9.50M – $10.00M | – | New | Mar 24, 2026 |
| full-year tax rate | FY2026 | 22.5% – 25% | – | New | Mar 24, 2026 |
| fully diluted shares outstanding | FY2026 | 62.3 | – | New | Mar 24, 2026 |
| interest income | FY2026 | $3.10M | – | Lowered | Mar 24, 2026 |
| Net incomeGAAP | FY2026 | $23.00M – $24.00M | – | New | Nov 9, 2026 |
| Net incomeGAAP | FY2026 | $21.50M – $23.00M | $13.00M – $16.00M | Raised | Aug 5, 2026 |
| Operating expenses | FY2026 | +20% | – | New | Mar 24, 2026 |
| Revenue growth (YoY) | FY2026 | +39% – +43% | – | Raised | Aug 5, 2026 |
| stock-based compensation | FY2026 | $5.50M | – | Lowered | Mar 24, 2026 |
Guidance vs results
The last range Paysign gave before each report, against the figure it then reported. Full years add up the four quarters.
| Period | Metric | Guidance | Actual | Result |
|---|---|---|---|---|
| Q3 FY2026 | EPS (GAAP) | $0.09 – $0.10 | $0.11 | Above range |
| Q3 FY2026 | Revenue | $28.50M – $30.00M | $30.80M | Above range |
| Q1 FY2026 | adjusted EBITDA per share | $0.15 – $0.16 | $0.17 | Above range |
| Q1 FY2026 | EPS (GAAP) | $0.07 – $0.08 | $0.09 | Above range |
| Q1 FY2026 | Revenue | $27.00M – $27.50M | $28.04M | Above range |
| Q1 FY2026 | Revenue growth | +45.2% – +47.8% | +50.75% | Above range |
| FY2025 | EPS (GAAP) | $0.12 – $0.13 | $0.13Σ4Q | Within range |
| FY2025 | Revenue | $80.50M – $81.50M | $82.04MΣ4Q | Above range |
| Q3 FY2025 | Revenue | $19.50M – $20.50M | $21.60M | Above range |
| Q2 FY2025 | Revenue | $18.50M – $19.00M | $19.08M | Above range |
| Q1 FY2025 | Revenue | $17.50M – $18.00M | $18.60M | Above range |
| Q2 FY2024 | Revenue growth | +27.5% | +30.27% | Above range |
| Q1 FY2024 | Revenue | $12.00M – $13.00M | $13.20M | Above range |
| Q1 FY2023 | Revenue | $10.20M – $10.30M | $10.10M | Below range |
Guidance history
Every forecast Paysign put in an earnings release, newest first
| Given | Metric | Period | Guidance | Change |
|---|---|---|---|---|
| Nov 9, 2026 | Adjusted EBITDA | FY2026 | $38.50M – $40.00M | New |
| Nov 9, 2026 | Diluted EPS | FY2026 | $0.37 – $0.38 | New |
| Nov 9, 2026 | Gross profit margin | FY2026 | 63.5% – 64.5% | New |
| Nov 9, 2026 | Net income | FY2026 | $23.00M – $24.00M | New |
| Nov 9, 2026 | Revenue | FY2026 | $114.00M – $117.00M | New |
| Aug 5, 2026 | Adjusted EBITDA | FY2026 | $35.00M – $38.00M | Raised |
| Aug 5, 2026 | Adjusted EBITDA | Q3 FY2026 | $9.50M – $10.00M | New |
| Aug 5, 2026 | Adj. EBITDA per diluted share | Q3 FY2026 | $0.15 – $0.16 | New |
| Aug 5, 2026 | Adj. EBITDA per diluted share | FY2026 | $0.57 – $0.61 | Raised |
| Aug 5, 2026 | Diluted EPS | FY2026 | $0.35 – $0.37 | Raised |
| Aug 5, 2026 | Diluted EPS | Q3 FY2026 | $0.09 – $0.10 | New |
| Aug 5, 2026 | Gross margin | Q3 FY2026 | 61% – 63% | New |
| Aug 5, 2026 | Gross margin | FY2026 | 62% – 63% | Raised |
| Aug 5, 2026 | plasma centers | Q3 FY2026 | 561 – 563 | Raised |
| Aug 5, 2026 | Revenue growth (YoY) | Q3 FY2026 | +32% – +38.9% | New |
| Aug 5, 2026 | Net income | Q3 FY2026 | $5.70M – $6.00M | New |
| Aug 5, 2026 | Revenue growth (YoY) | FY2026 | +39% – +43% | Raised |
| Aug 5, 2026 | Net income | FY2026 | $21.50M – $23.00M | Raised |
| Aug 5, 2026 | active patient affordability programs | Q3 FY2026 | 165 – 170 | New |
| Aug 5, 2026 | Revenue | FY2026 | $114.00M – $117.00M | Raised |
| Aug 5, 2026 | Revenue | Q3 FY2026 | $28.50M – $30.00M | New |
| May 12, 2026 | plasma centers | Q2 FY2026 | 555 – 560 | Raised |
| May 12, 2026 | active patient affordability programs | Q2 FY2026 | 147 – 150 | New |
| Mar 24, 2026 | adjusted EBITDA | FY2026 | $30.00M – $33.00M | New |
| Mar 24, 2026 | adjusted EBITDA per diluted share | FY2026 | $0.49 – $0.53 | New |
| Mar 24, 2026 | adjusted EBITDA per share | Q1 FY2026 | $0.15 – $0.16 | New |
| Mar 24, 2026 | diluted share | FY2026 | $0.21 – $0.26 | New |
| Mar 24, 2026 | Fully diluted earnings per share | Q1 FY2026 | $0.07 – $0.08 | New |
| Mar 24, 2026 | Gross profit margins | FY2026 | 60% – 62% | New |
| Mar 24, 2026 | operating margin | Q1 FY2026 | 20% – 22% | New |
| Mar 24, 2026 | fully diluted shares outstanding | FY2026 | 62.3 | New |
| Mar 24, 2026 | full-year tax rate | FY2026 | 22.5% – 25% | New |
| Mar 24, 2026 | Operating expenses | FY2026 | +20% | New |
| Mar 24, 2026 | depreciation and amortization expense | FY2026 | $9.50M – $10.00M | New |
| Mar 24, 2026 | stock-based compensation | FY2026 | $5.50M | Lowered |
| Mar 24, 2026 | interest income | FY2026 | $3.10M | Lowered |
| Mar 24, 2026 | Net income | FY2026 | $13.00M – $16.00M | New |
| Mar 24, 2026 | active patient affordability programs | Q1 FY2026 | 137 | New |
| Mar 24, 2026 | plasma centers | Q1 FY2026 | 589 | Raised |
| Mar 24, 2026 | net margin | Q1 FY2026 | 17% – 19% | New |
| Mar 24, 2026 | adjusted EBITDA margin | Q1 FY2026 | 34.5% – 36.5% | New |
| Mar 24, 2026 | year-over-year growth | FY2026 | +30% – +35% | New |
| Mar 24, 2026 | revenue | FY2026 | $106.50M – $110.50M | New |
| Mar 24, 2026 | growth over first quarter 2025 | Q1 FY2026 | +45.2% – +47.8% | New |
| Mar 24, 2026 | revenue | Q1 FY2026 | $27.00M – $27.50M | New |
| Nov 12, 2025 | Adjusted EBITDA | FY2025 | $19.00M – $20.00M | New |
| Nov 12, 2025 | Adjusted EBITDA per diluted share | FY2025 | $320.00K – $340.00K | New |
| Nov 12, 2025 | net income per diluted share | FY2025 | $0.12 – $0.13 | New |
| Nov 12, 2025 | gross profit margins | FY2025 | 60% | New |
| Nov 12, 2025 | depreciation and amortization expenses | FY2025 | $8.40M | Lowered |
| Nov 12, 2025 | stock-based compensation expense | FY2025 | $4.30M | Lowered |
| Nov 12, 2025 | net income | FY2025 | $7.00M – $8.00M | New |
| Nov 12, 2025 | Interest income | FY2025 | $2.60M | Lowered |
| Nov 12, 2025 | fully diluted share count | FY2025 | 59.76 | New |
| Nov 12, 2025 | tax rate | FY2025 | 18.7% | New |
| Nov 12, 2025 | operating expenses | FY2025 | $41.50M – $42.50M | New |
| Nov 12, 2025 | total revenues | FY2025 | $80.50M – $81.50M | New |
| Aug 5, 2025 | Adjusted EBITDA | Q3 FY2025 | $4.50M – $5.00M | New |
| Aug 5, 2025 | Adjusted EBITDA | FY2025 | $18.00M – $20.00M | Raised |
| Aug 5, 2025 | Adjusted EBITDA per diluted share | FY2025 | $0.31 – $0.35 | Raised |
| Aug 5, 2025 | net income per diluted share | FY2025 | $0.10 – $0.12 | Reaffirmed |
| Aug 5, 2025 | Gross profit margins | Q3 FY2025 | 59% | New |
| Aug 5, 2025 | gross profit margins | FY2025 | 61% – 62% | Lowered |
| Aug 5, 2025 | Operating expenses | Q3 FY2025 | $10.50M – $11.50M | New |
| Aug 5, 2025 | Adjusted EBITDA as percentage of revenue | Q3 FY2025 | 23.1% – 24.4% | New |
| Aug 5, 2025 | depreciation and amortization | Q3 FY2025 | $2.20M | Lowered |
| Aug 5, 2025 | stock-based compensation | Q3 FY2025 | $1.40M | Lowered |
| Aug 5, 2025 | diluted share count | FY2025 | 57.5 | Raised |
| Aug 5, 2025 | operating expenses | FY2025 | $41.00M – $43.00M | Raised |
| Aug 5, 2025 | depreciation and amortization expense | FY2025 | $8.40M | Lowered |
| Aug 5, 2025 | stock-based compensation | FY2025 | $4.40M | Lowered |
| Aug 5, 2025 | Interest income | FY2025 | $2.50M | Lowered |
| Aug 5, 2025 | net income | FY2025 | $6.00M – $7.00M | Reaffirmed |
| Aug 5, 2025 | total revenues | FY2025 | $76.50M – $78.50M | Raised |
| Aug 5, 2025 | total revenues year-over-year growth | FY2025 | +32.7% | Raised |
| Aug 5, 2025 | total revenue | Q3 FY2025 | $19.50M – $20.50M | New |
| May 8, 2025 | Adjusted EBITDA | FY2025 | $16.00M – $17.00M | Raised |
| May 8, 2025 | Adjusted EBITDA | Q2 FY2025 | $4.50M – $5.00M | New |
| May 8, 2025 | Adjusted EBITDA per diluted share | FY2025 | $0.28 – $0.30 | Raised |
| May 8, 2025 | net income per diluted share | FY2025 | $0.10 – $0.12 | Raised |
| May 8, 2025 | gross profit margins | FY2025 | 62% – 64% | Reaffirmed |
| May 8, 2025 | Gross profit margins | Q2 FY2025 | 63% – 64% | New |
| May 8, 2025 | Adjusted EBITDA margin | Q2 FY2025 | 25.5% | New |
| May 8, 2025 | Interest income | FY2025 | $2.90M | Lowered |
| May 8, 2025 | depreciation and amortization expense | FY2025 | $8.00M | Lowered |
| May 8, 2025 | stock-based compensation | FY2025 | $3.80M | Lowered |
| May 8, 2025 | net income | FY2025 | $6.00M – $7.00M | New |
| May 8, 2025 | Operating expenses | Q2 FY2025 | $10.00M – $11.00M | New |
| May 8, 2025 | depreciation and amortization | Q2 FY2025 | $2.00M | Lowered |
| May 8, 2025 | stock-based compensation | Q2 FY2025 | $1.00M | Lowered |
| May 8, 2025 | diluted share count | FY2025 | 56 | New |
| May 8, 2025 | Plasma revenue year-over-year decline | FY2025 | -10% – -8% | New |
| May 8, 2025 | Operating expenses | FY2025 | $41.00M – $43.00M | Raised |
| May 8, 2025 | year-over-year growth | FY2025 | +25% | Raised |
| May 8, 2025 | total revenues | FY2025 | $72.00M – $74.00M | Raised |
| May 8, 2025 | total revenue | Q2 FY2025 | $18.50M – $19.00M | New |
| Mar 25, 2025 | Adjusted EBITDA | Q1 FY2025 | $4.00M – $5.00M | New |
| Mar 25, 2025 | adjusted EBITDA | FY2025 | $12.50M – $13.50M | New |
| Mar 25, 2025 | adjusted EBITDA ... per diluted share | FY2025 | $0.22 – $0.24 | New |
| Mar 25, 2025 | diluted share | FY2025 | $0.00 | New |
| Mar 25, 2025 | Gross profit margins | Q1 FY2025 | 63% – 64% | New |
| Mar 25, 2025 | gross profit margins | FY2025 | 62% – 64% | New |
| Mar 25, 2025 | interest income | FY2025 | $2.80M | Lowered |
| Mar 25, 2025 | Operating expenses | FY2025 | $47.50M – $50.00M | New |
| Mar 25, 2025 | Operating expenses | Q1 FY2025 | $10.50M – $11.00M | New |
| Mar 25, 2025 | depreciation and amortization | Q1 FY2025 | $1.90M | Lowered |
| Mar 25, 2025 | stock-based compensation | Q1 FY2025 | $2.10M | Raised |
| Mar 25, 2025 | Depreciation and amortization expense | FY2025 | $10.50M – $11.50M | Lowered |
| Mar 25, 2025 | stock-based compensation | FY2025 | $6.00M | Lowered |
| Mar 25, 2025 | total revenue | Q1 FY2025 | $17.50M – $18.00M | New |
| Mar 25, 2025 | total revenues year-over-year growth | FY2025 | +17.5% – +20% | New |
| Mar 25, 2025 | total revenues | FY2025 | $68.50M – $70.00M | New |
| Nov 5, 2024 | adjusted EBITDA | FY2024 | $9.00M – $10.00M | Reaffirmed |
| Nov 5, 2024 | adjusted EBITDA per fully diluted share | FY2024 | $0.16 – $0.18 | Reaffirmed |
| Nov 5, 2024 | pharma patient affordability revenue percentage of total revenues | FY2024 | 20% | Lowered |
| Nov 5, 2024 | adjusted EBITDA (percentage of total revenues) | FY2024 | 15% – 17% | New |
| Nov 5, 2024 | total revenues | FY2024 | $56.50M – $58.50M | Reaffirmed |
| Jul 31, 2024 | adjusted EBITDA | FY2024 | $9.00M – $10.00M | Raised |
| Jul 31, 2024 | adjusted EBITDA ... per diluted share | FY2024 | $0.16 – $0.18 | Raised |
| Jul 31, 2024 | diluted share | FY2024 | $0.04 – $0.06 | Reaffirmed |
| Jul 31, 2024 | gross profit margins | FY2024 | 54% – 55% | Raised |
| Jul 31, 2024 | fully diluted share count outstanding | FY2024 | 55.8 – 56 | New |
| Jul 31, 2024 | tax rate | FY2024 | 28% – 29% | New |
| Jul 31, 2024 | Operating expenses | FY2024 | $30.00M – $32.00M | Raised |
| Jul 31, 2024 | interest income | FY2024 | $3.00M – $3.20M | Lowered |
| Jul 31, 2024 | net income | FY2024 | $2.00M – $3.00M | Reaffirmed |
| Jul 31, 2024 | total revenues | FY2024 | $56.50M – $58.50M | Raised |
| May 7, 2024 | adjusted EBITDA | Q2 FY2024 | +65% – +70% | New |
| May 7, 2024 | adjusted EBITDA | FY2024 | $8.00M – $9.00M | Reaffirmed |
| May 7, 2024 | pharma revenue accounting for approximately | Q2 FY2024 | 18% | New |
| May 7, 2024 | adjusted EBITDA margin | Q2 FY2024 | 13.5% – 14% | New |
| May 7, 2024 | total revenue | Q2 FY2024 | +27.5% | New |
| May 7, 2024 | total revenues | FY2024 | $54.50M – $56.70M | Reaffirmed |
| Mar 26, 2024 | adjusted EBITDA | FY2024 | $8.00M – $9.00M | New |
| Mar 26, 2024 | adjusted EBITDA... per diluted share | FY2024 | $0.15 – $0.17 | New |
| Mar 26, 2024 | per diluted share | FY2024 | $0.04 – $0.06 | New |
| Mar 26, 2024 | gross profit margins | Q1 FY2024 | 52% – 53% | New |
| Mar 26, 2024 | gross profit margins | FY2024 | 52% – 54% | New |
| Mar 26, 2024 | Operating expenses | Q1 FY2024 | $7.00M – $7.50M | New |
| Mar 26, 2024 | depreciation and amortization | Q1 FY2024 | $1.30M | Lowered |
| Mar 26, 2024 | Operating expenses | FY2024 | $29.00M – $31.00M | New |
| Mar 26, 2024 | depreciation and amortization | FY2024 | $6.00M – $6.50M | Lowered |
| Mar 26, 2024 | stock-based compensation | FY2024 | $2.70M – $3.00M | Lowered |
| Mar 26, 2024 | interest income | FY2024 | $2.60M – $2.90M | Lowered |
| Mar 26, 2024 | net income | FY2024 | $2.00M – $3.00M | New |
| Mar 26, 2024 | total revenue | Q1 FY2024 | $12.00M – $13.00M | New |
| Mar 26, 2024 | total revenues | FY2024 | $54.50M – $56.70M | New |
| Nov 7, 2023 | Adjusted EBITDA | FY2023 | $6.00M – $7.50M | Reaffirmed |
| Nov 7, 2023 | operating expenses | Q4 FY2023 | $6.30M | New |
| Nov 7, 2023 | revenue | FY2023 | $44.00M – $46.00M | Reaffirmed |
| Aug 8, 2023 | Adjusted EBITDA | FY2023 | $6.00M – $7.50M | Reaffirmed |
| Aug 8, 2023 | revenue | FY2023 | $44.00M – $46.00M | Reaffirmed |
| May 10, 2023 | Adjusted EBITDA | Q2 FY2023 | +5% – +10% | New |
| May 10, 2023 | total revenue | Q2 FY2023 | +15% – +20% | New |
| Mar 21, 2023 | Adjusted EBITDA | Q1 FY2023 | $700.00K – $800.00K | New |
| Mar 21, 2023 | adjusted EBITDA | FY2023 | $6.00M – $7.50M | New |
| Mar 21, 2023 | adjusted EBITDA per diluted share | FY2023 | $0.11 – $0.14 | New |
| Mar 21, 2023 | diluted share | FY2023 | $0.05 – $0.06 | New |
| Mar 21, 2023 | gross profit margins | Q1 FY2023 | 52.5% – 53.5% | New |
| Mar 21, 2023 | gross profit margins | FY2023 | 52.5% – 55% | New |
| Mar 21, 2023 | Operating expenses | Q1 FY2023 | $6.20M – $6.40M | New |
| Mar 21, 2023 | Operating expenses | FY2023 | $23.00M – $25.00M | New |
| Mar 21, 2023 | total revenue | Q1 FY2023 | $10.20M – $10.30M | New |
| Mar 21, 2023 | total revenue | FY2023 | $44.00M – $46.00M | New |
| Nov 8, 2022 | Adjusted EBITDA | FY2022 | $5.50M – $5.60M | Raised |
| Nov 8, 2022 | gross profit margins | FY2022 | 56% | Raised |
| Nov 8, 2022 | operating expenses | FY2022 | $21.00M – $21.25M | Raised |
| Nov 8, 2022 | depreciation and amortization | FY2022 | $2.91M | Lowered |
| Nov 8, 2022 | stock-based compensation | FY2022 | $2.28M | Lowered |
| Nov 8, 2022 | total revenue | FY2022 | $38.15M – $38.35M | Raised |
| May 11, 2022 | Adjusted EBITDA | FY2022 | $4.00M | Reaffirmed |
| May 11, 2022 | gross profit margins | FY2022 | 50% – 52.5% | Reaffirmed |
| May 11, 2022 | Operating expenses | FY2022 | $20.00M | Raised |
| May 11, 2022 | Depreciation and amortization | FY2022 | $3.00M – $3.25M | Lowered |
| May 11, 2022 | stock-based compensation | FY2022 | $2.00M | New |
| May 11, 2022 | total revenue | FY2022 | $35.25M – $38.35M | Reaffirmed |
| Mar 22, 2022 | Adjusted EBITDA | FY2022 | $4.00M | New |
| Mar 22, 2022 | gross profit margin | Q1 FY2022 | 60% | New |
| Mar 22, 2022 | gross profit margins | FY2022 | 50% – 52.5% | New |
| Mar 22, 2022 | Operating expenses | FY2022 | $20.00M | New |
| Mar 22, 2022 | Depreciation and amortization | FY2022 | $3.00M – $3.25M | Lowered |
| Mar 22, 2022 | stock-based compensation | FY2022 | $2.00M | Lowered |
| Mar 22, 2022 | total revenue | FY2022 | $35.25M – $38.35M | New |
| Nov 9, 2021 | adjusted EBITDA | FY2021 | $1.30M – $1.90M | New |
| Nov 9, 2021 | gross profit margin | FY2021 | 49% | New |
| Nov 9, 2021 | stock-based compensation expense | FY2021 | $2.40M | New |
| Nov 9, 2021 | operating expenses | FY2021 | $17.60M – $17.80M | New |
| Nov 9, 2021 | Depreciation and amortization expense | FY2021 | $2.50M | Lowered |
Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.
Press releases
Releases Paysign filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Results
- Update
- Update
- Update
- Results
- Results
- Results
- Results
- Results
- Results
- Results
See a number that looks wrong?